Sort by

Send to

Choose Destination

Search results

Items: 4


Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, Naidoo J, Fay J, Kay E, Carr A, Kennedy S, Furney S, Mezynski J, Breathhnach O, Morris P, Grogan L, Hill A, Kennedy S, Crown J, Gallagher W, Hennessy B, Eustace A.

Ther Adv Med Oncol. 2018 Jul 13;10:1758835918778297. doi: 10.1177/1758835918778297. eCollection 2018.


Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells.

Kavanagh EL, Lindsay S, Halasz M, Gubbins LC, Weiner-Gorzel K, Guang MHZ, McGoldrick A, Collins E, Henry M, Blanco-Fernández A, O Gorman P, Fitzpatrick P, Higgins MJ, Dowling P, McCann A.

Oncogenesis. 2017 Oct 9;6(10):e388. doi: 10.1038/oncsis.2017.82.


The fate of chemoresistance in triple negative breast cancer (TNBC).

O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A.

BBA Clin. 2015 Mar 12;3:257-75. doi: 10.1016/j.bbacli.2015.03.003. eCollection 2015 Jun. Review.


Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.

Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D, O'Sullivan J, Murphy M, Madden SF, Kell M, McCann A, Furlong F.

Cancer Med. 2015 May;4(5):745-58. doi: 10.1002/cam4.409. Epub 2015 Feb 15.

Supplemental Content

Loading ...
Support Center